A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection （a humanized anti-PD-1 monoclonal antibody）in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: QL1604 injection
Dose-limiting toxicity (DLT), Dose-limiting toxicity (DLT), Up to 21 days after the first dose|maximum tolerated dose(MTD), maximum tolerated dose(MTD), Up to 21 days after the first dose|recommended phase II dose (RP2D), recommended phase II dose (RP2D), up to 2 years
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, according to NCI CTCAE V5.0, up to 2 years|Maximum Concentration (Cmax) of QL1604 in Solid Tumor Participants, Maximum Concentration (Cmax), up to 2 years|Time to Maximum Concentration (Tmax) of QL1604 in Solid Tumor Participants, Time to Maximum Concentration (Tmax), up to 2 years|Terminal Half-Life (t ½) of QL1604 in Solid Tumor Participants, Terminal Half-Life (t ½), up to 2 years|Area Under the Concentration-Time Curve of QL1604 From Time 0 to Day 28 (AUC 0-22) in Solid Tumor Participants, Area Under the Concentration-Time Curve, up to 22 days|Objective Response Rate (ORR) According to RECIST 1.1, Objective Response Rate (ORR) According to RECIST 1.1, up to 2 years|Disease Control Rate (DCR) According to RECIST 1.1, Disease Control Rate (DCR) According to RECIST 1.1, up to 2 years
This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection （a humanized anti-PD-1 monoclonal antibody）in patients with advanced solid tumors.